Iberdomide Maintenance Therapy
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
What will happen during the trial?
This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or toxicity. A maximum of 38 participants will be enrolled. The results from this study will inform the feasibility of pursuing a phase 3 study comparing iberdomide to lenalidomide maintenance post-ASCT.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 38 patients (estimated)
- Sponsors
- University of Nebraska Medical Center
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Maintenance
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1233
- NCT Identifier
- NCT05177536
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.